Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 2

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 2
---
 IN, JP, KR, US, ZA
     
    2032

    VXM01 – dosing (2)
    WO 2014/005683, DNA Vaccine for Use in Pancreatic Cancer Patients
     
    Owned
     
    Formulation
     
    AU, CN, EP, JP, KR, US, ZA
     
    2033

    VXM06 – WT1 (3)
    WO 2014/173542, Salmonella-based vectors for cancer immunotherapy
    targeting Wilms’ tumor gene
     
    Owned
     
    Composition of Matter
     
    EP, JP, US
     
    2034

    VXM04-MSLN (4)
    WO 2015/090584, Novel MSLN targeting DNA vaccine for cancer immunotherapy
     
    Owned
     
    Composition of Matter
     
    EP, JP, US
     
    2034

    VXM01 – combination (5)
    WO 2016/202459, VEGFR-2 targeting DNA vaccine for combination
    therapy
     
    Owned
     
    Composition of Matter; Method of Use
     
    AU, CA, CN, EP, IN, US, ZA
     
    2036

    VXM01 Tumor expression (7)
    WO 2018/149982, Novel VEGFR-2 targeting immunotherapy approach
     
    Owned
     
    Composition of Matter
     
    AU, US
     
    2038
  
    Darnatein

    Designer ligands of TGF-ß superfamily (0)
    WO 2010/099219
     
    Exclusive License
     
    Composition of Matter
     
    EP, KR, JP
     
    2030

Individual patents are in force for varying periods of time, depending
upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which
they are obtained. Generally, patents issued for applications filed in the United States are in force for 20 years from the
earliest nonprovisional filing date. In addition, in certain instances, a patent term can be adjusted or extended to recapture a portion